DrugRepV|Encyclopedia for antivirals

Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_4794

Chemical Information
Antiviral agent ID DrugRepV_4794
Antiviral agent name 3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
IUPAC Name 3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
SMILES (canonical) [H]C1=CC=C([H])C(=C1)C1=CC=C(O1)\C=C1/C(=O)N(N=C1C1=CC=CC=C1)C1=CC=CC(=C1)C(O)=O
Molecular Formula C27H18N2O4
Molecular Weight (g/mol) 434.451

InChl InChI=1S/C27H18N2O4/c30-26-23(17-22-14-15-24(33-22)18-8-3-1-4-9-18)25(19-10-5-2-6-11-19)28-29(26)21-13-7-12-20(16-21)27(31)32/h1-17H,(H,31,32)/b23-17-
Structural Information

Clinical Information
Biological Information
Secondary Indication Severe acute respiratory syndrome coronavirus (SARS-CoV) NA NA
Secondary Indication (Approaches) Experimental
Secondary Indication (Methods) In-vitro
Secondary Indication (Drug concentration) 6.4 ± 1.2 μM
Secondary Indication (Change) Decrease
Secondary Indication (Type of Inhibition) IC50 [ 50 % ]
Reference Kumar V, Tan KP, Wang YM, Lin SW, Liang PH..Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors..Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. doi: 10.1016/j.bmc.2016.05.013. Epub 2016 May 12. PMID:27240464
Comment Docking studies show that a carboxylate present at either R¹ or R⁴ destabilizes the oxyanion hole in the 3CL^pro. Compounds 3f, 3g and 3m could inhibit both NA and 3CLpro and serve as a starting point to develop broad-spectrum antiviral agents.

Copyright © 2019. CSIR-Institute of Microbial Technology, Chandigarh, INDIA.

Chemical Information
Antiviral agent ID	DrugRepV_4794
Antiviral agent name	3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
IUPAC Name	3-[(4Z)-5-oxo-3-phenyl-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
SMILES (canonical)	[H]C1=CC=C([H])C(=C1)C1=CC=C(O1)\C=C1/C(=O)N(N=C1C1=CC=CC=C1)C1=CC=CC(=C1)C(O)=O
Molecular Formula	C27H18N2O4
Molecular Weight (g/mol)	434.451
InChl	InChI=1S/C27H18N2O4/c30-26-23(17-22-14-15-24(33-22)18-8-3-1-4-9-18)25(19-10-5-2-6-11-19)28-29(26)21-13-7-12-20(16-21)27(31)32/h1-17H,(H,31,32)/b23-17-
Structural Information

Clinical Information
Biological Information
Secondary Indication	Severe acute respiratory syndrome coronavirus (SARS-CoV) NA NA
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Drug concentration)	6.4 ± 1.2 μM
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	IC50 [ 50 % ]
Reference	Kumar V, Tan KP, Wang YM, Lin SW, Liang PH..Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors..Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. doi: 10.1016/j.bmc.2016.05.013. Epub 2016 May 12. PMID:27240464
Comment	Docking studies show that a carboxylate present at either R¹ or R⁴ destabilizes the oxyanion hole in the 3CL^pro. Compounds 3f, 3g and 3m could inhibit both NA and 3CLpro and serve as a starting point to develop broad-spectrum antiviral agents.